India faces a multitude of challenges on different levels- social, economic and healthcare systems. In the context of the healthcare system, there are inadequately trained staff involved in the management of T1D, a lack of a structured diabetes education program, lack of free supplies of insulin and glucose meters and strips. In such a scenario, this approach can act as a helpful resource in managing T1D, to optimize therapeutic outcomes and provide the best care possible [5]. The approach (Figure 1) has been prepared considering the consensus of the International Society of Adolescent and Pediatric Diabetes (ISPAD) Clinical Practice Consensus Guidelines 2022: Management of the Child, adolescent, and young adult with Diabetes in limited resource settings [6] and the recommendation by the American Diabetes Association (ADA) [7].
Alphabetical approach
Figure 1: Management of type 1 diabetes presented alphabetically. The inner circle represents the minimum that needs to be undertaken for PwD. The outer circle represents the comprehensive care required in restricted settings.
- Accurate diagnosis
The diagnosis of T1D is based on elevated plasma glucose levels and HbA1c. One must pay attention to the history given by the family/caregiver. Symptoms include glycosuria, which causes polyuria and nocturia, and uninhibited gluconeogenesis due to lack of insulin, which causes protein and fat breakdown, resulting in dramatic weight loss, emaciation and failure to thrive may be the first noticeable symptoms in children. In addition, persistent hyperglycemia can lead to diabetic ketoacidosis, which requires hospitalization. Measurement of islet autoantibodies, C-peptide, or genetic testing is not routinely recommended for the diagnosis of T1D in LRS, and can be done if the type of diabetes is unclear [6]. The American Diabetes Association (ADA) 2024 Standard of Care recommends testing for antibodies, mainly glutamic acid decarboxylase (GAD), for further confirmation. If negative, islet tyrosine phosphatase 2 (IA-2) and/or zinc transporter 8 (ZnT8) should be followed. C-peptide values should be checked when hyperglycemic crises resolve. C-peptide values of 0.6-1.8 ng/mL are generally consistent with a confirmatory diagnosis of T1D [7].
At certain constraints settings, there is no facility to perform genetic tests. Moreover, the cost of the tests is higher and affordability is the major issue. In such scenarios, diagnosis can be confirmed from elevated plasma glucose levels, higher HbA1c and a history of DKA at diagnosis.
Administration of insulin, storage, and disposal
Insulin should be injected into the subcutaneous tissue at the abdomen, lateral aspect of the arm, front of thighs/lateral thighs, or lateral upper quadrant of the buttocks. In the same sequence, the rate of absorption is quick, intermediate, and slow.